Cellares vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cellares is the first Integrated Development and Manufacturing Organization (IDMO) for cell therapy, automating end-to-end CAR-T and cell therapy production; raised $257M Series D in 2026 led by BlackRock and Eclipse;
About
Cellares is a clinical-stage biotech and contract manufacturing company founded in 2019 by Fabian Gerlinghaus, James Cha, and Yi Zhao, headquartered in South San Francisco, California. The company has built the world''s first fully automated, integrated cell therapy manufacturing platform — the Cell Shuttle — which automates the entire end-to-end process of manufacturing patient-specific T-cell therapies (including CAR-T cells) in a single closed system. Traditional cell therapy manufacturing is highly manual, requiring highly trained technicians, specialized cleanroom infrastructure, and weeks of labor-intensive processing. Cellares replaces this with industrial-scale automation, compressing production timelines and dramatically reducing the cost and variability of cell therapy manufacturing.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.